Search results for " Antibodies"

showing 10 items of 383 documents

Clinical evaluation and applications of the Amplicor HBV Monitor™ test, a quantitative HBV DNA PCR assay

1998

Viral load has emerged recently as a reliable marker of disease progression and therapeutic efficacy in chronic infections, including AIDS and hepatitis C. The clinical management of type B hepatitis could also be improved by monitoring viremia levels in patients with chronic liver disease undergoing anti-viral treatment. To address this question we evaluated the performance of a newly developed, quantitative PCR assay (Amplicor HBV Monitor test, Roche Diagnostic Systems) in the assessment of viremia changes over time in a group of 45 patients with chronic active hepatitis (CAH) who received interferon treatment. Of the 45 patients, 14 were HBsAg and anti-HBeAg positive and 31 HBsAg, HBeAg …

AdultMaleHepatitis B virusHBsAgImmunoblottingViremiaBiologymedicine.disease_causePolymerase Chain ReactionHepatitis B ChronicVirologymedicineHumansHepatitis B e AntigensViremiaHepatitis B AntibodiesHepatitisHepatitis B virusHepatitis B Surface AntigensInterferon-alphavirus diseasesAlanine TransaminaseMiddle AgedViral LoadHepatitis Bmedicine.diseasebiology.organism_classificationVirologydigestive system diseasesTreatment OutcomeImmunoglobulin MHBeAgHepadnaviridaeEvaluation Studies as TopicDNA ViralImmunologyFemaleViral loadJournal of Virological Methods
researchProduct

Rare pre-core stop-codon mutant nt. 1897 predominates over wide-spread mutant nt. 1896 in an unusual course of chronic hepatitis B

1996

We present a patient with an unusual course of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B who had repeated reactivations of his disease progressing to cirrhosis with terminal liver failure. Each flare up presented like an acute hepatitis with very high titres of hepatitis B virus (HBV) and high inflammatory activity followed by rapid clearance of viraemia. The pre-core genome of HBV isolated from sera during 5 years of follow up was analysed. Direct sequencing of polymerase chain reaction (PCR) products derived from consecutive sera showed a rare pre-core stop-codon mutation at nucleotide (nt.) 1897 G --> A with an accompanying mutation nt. 1857 C --> T as well as a stop-cod…

AdultMaleHepatitis B virusMolecular Sequence DataMutantBiologymedicine.disease_causePolymerase Chain ReactionHepatitis B virus PRE betaVirusVirologymedicineHumansHepatitis B e AntigensHepatitis B AntibodiesHepatitis B virusMutationHepatitis B Surface AntigensBase SequenceHepatologyHepatitis BHepatitis B Core AntigensVirologyMolecular biologyStop codonInfectious DiseasesLiverViral replicationHBeAgChronic DiseaseDNA ViralMutationCodon TerminatorLiver FailureSignal TransductionT-Lymphocytes Cytotoxic
researchProduct

Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study

2010

To compare the management and the virological and serological efficacy of treatments for chronic hepatitis B (CHB) in HIV positive and negative patients.Two hundred and forty-six HIV positive and 205 HIV negative consecutive patients with past or present CHB, seen in October 2008 in participating departments, were included in a multicenter study. All the data were retrospectively collected from the first visit to October 2008 through a standardized questionnaire.Compared to HIV negative patients, HIV positive patients more often presented positive HBeAg (46.4% vs. 32.8%, p=0.01), HBV genotype A (54.8% vs. 17.1%, p0.0001), co-infection with HCV (12.4% vs. 5.9%, p=0.0002) or HDV (12.6% vs. 2.…

AdultMaleHepatitis B virusmedicine.medical_specialtyOrganophosphonatesHIV InfectionsAntiviral AgentsSerologyHepatitis B AntigensHepatitis B ChronicPharmacotherapyAcquired immunodeficiency syndrome (AIDS)Surveys and QuestionnairesInternal medicinemedicineHumansHepatitis B AntibodiesTenofovirSidaRetrospective StudiesHepatologybiologybusiness.industryAdeninevirus diseasesMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseHBeAgLentivirusImmunologyFemaleFranceViral diseasebusinessJournal of Hepatology
researchProduct

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C

2003

Occult HBV infection in subjects with chronic hepatitis C is related to more severe disease outcome. It has been suggested that it might reduce sensitivity to antiviral treatment.To assess in HBsAg negative subjects with chronic hepatitis C any effect of the presence of HBV genomes in the liver on the early kinetics of HCV-RNA under PEG-IFN plus ribavirin.Twenty-two anti-HCV and HCV-RNA positive subjects, with biopsy-proven chronic hepatitis C (M/F 15/7; 50 +/- 8.6 years, 16 genotype 1b) were given PEG-IFN alpha 2b 1.0 microg qw plus ribavirin (800 to 1,200 mg daily according to body weight) for an intended 52 week period. Early virological response was assessed over the first 4 weeks of th…

AdultMaleHepatitis B viruspegylated interferon-alphaGenotypeBiopsyHepacivirusInterferon alpha-2Virus ReplicationAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodieRibavirinchronic hepatitis CHumansHepatitis B AntibodiesAntiviral AgentHepaciviruoccult HBV infection; chronic hepatitis C; pegylated interferon-alpha; viral dynamics; treatment responseoccult HBV infectiontreatment responseInterferon-alphaAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesHepatitis C ChronicMiddle AgedRecombinant ProteinViral LoadHepatitis Bviral dynamicsRecombinant ProteinsTreatment OutcomeLiverDNA ViralRNA ViralDrug Therapy CombinationFemaleHepatitis C AntibodieHuman
researchProduct

IgM and IgG antibodies to hepatitis C virus in patients with mixed cryoglobulinaemia

1993

SUMMARY To assess the relationship between hepatitis C virus (HCV) infection and essential mixed cryoglobulinaemia (EMC), sera from 23 patients with EMC were tested for IgG and IgM antibodies to HCV antigens and for HCV RNA. Quantitative HCV antibody studies were performed on scrum and purified cryoglobulin fractions. HCV antibodies of both IgG and IgM class were found in 22 (96%) patients. Ten of these were also HCV-RNA positives. Higher litres of anti-HCV IgM were present in the 11 patients with evidence of liver damage. Anti-HCV IgG antibodies were shown to be concentrated in the IgG fraction of cryoglobulins in all eight patients studied. These results strongly suggest a role for HCV in…

AdultMaleHepatitis C virusImmunologyHepacivirusmedicine.disease_causeVirusCryoglobulinsSerologyFlaviviridaeAntigenmedicineHumansImmunology and AllergyHepatitis AntibodiesAgedbiologyvirus diseasesHepatitis C AntibodiesMiddle Agedbiology.organism_classificationHepatitis CVirologydigestive system diseasesCryoglobulinemiaImmunoglobulin MImmunoglobulin GHumoral immunityImmunologybiology.proteinRNA ViralFemaleAntibodyResearch ArticleClinical and Experimental Immunology
researchProduct

Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis

1992

Hepatitis C virus (HCV) replication was assessed before and during alpha-interferon (IFN) treatment in 22 anti-HCV positive patients with posttransfusion or sporadic chronic hepatitis (CH). Eleven patients were “responders” and 11 patients “non-responders” to IFN. Thirteen anti-HCV negative healthy subjects and five anti-HCV negative patients with autoimmune CH served as controls. Serum HCV-RNA was detected by the polymerase chain reaction (PCR) in all untreated anti-HCV positive patients but in none of the anti-HCV negative subjects. PCR primers from the 5′-non-coding (NC) region were more sensitive than primers from a non-structural (NS5) region in detecting HCV-RNA (21/22, 95% vs. 7/22, …

AdultMaleHepatitis C virusMolecular Sequence DataDNA Single-StrandedAlpha interferonHepacivirusAutoimmune hepatitisInterferon alpha-2Virus Replicationmedicine.disease_causePolymerase Chain ReactionSensitivity and SpecificityVirusInterferonVirologymedicineHumansHepatitis AntibodiesViremiaBase Sequencebiologybusiness.industryInterferon-alphavirus diseasesHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CVirologyRecombinant ProteinsTiterInfectious DiseasesChronic DiseaseImmunologybiology.proteinRNA ViralFemaleViral diseaseAntibodybusinessmedicine.drugJournal of Medical Virology
researchProduct

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Stu…

2016

International audience;  Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of 100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.

AdultMaleHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusSerology03 medical and health sciences0302 clinical medicineImmunogenicity Vaccine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveHepatitis B virus HBVImmunology and AllergyMedicineHumansHepatitis B Vaccines030212 general & internal medicineProspective StudiesHepatitis B AntibodiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyVaccines Syntheticbiologybusiness.industryImmunogenicityvirus diseasesMiddle AgedHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyImmunologybiology.proteinHIV-1030211 gastroenterology & hepatologyFemaleAntibodybusiness
researchProduct

Third-generation hepatitis C virus tests in asymptomatic anti-HCV-positive blood donors

1994

This study evaluated the performance of third-generation anti-HCV assays in blood donors who were positive by second-generation anti-HCV, and assessed any possible relationship between antibody patterns, HCV replication and liver damage. Fifty-two second-generation enzyme immunoassay-positive asymptomatic Italian blood donors were retested for anti-HCV by third-generation enzyme immunoassay and recombinant immunoblot assay (Ortho third-generation enzyme immunoassay, third-generation recombinant immunoblot assay), utilising recombinant C33c and NS5 and synthetic peptide C100 and C22 antigens, and for HCV-RNA by "nested" polymerase chain reaction with 5' region primers. Alanine aminotransfera…

AdultMaleMicrobiological TechniquesHepatitis C virusImmunoblottingBlood DonorsHepacivirusmedicine.disease_causeVirusSerologylaw.inventionCohort StudiesImmunoenzyme TechniquesAntigenlawmedicineHumansHepatitis AntibodiesPolymerase chain reactionHepatologybiologymedicine.diagnostic_testMiddle AgedVirologyImmunoassaybiology.proteinRecombinant DNARNA ViralFemaleAntibodyJournal of Hepatology
researchProduct

Immunohistological and immunoelectron microscopic identification of TNF alpha in normal human and murine epidermis.

1992

The presence, distribution and cellular localization of tumour necrosis factor-alpha (TNF alpha) were investigated in normal human and murine epidermis using immunohistological and immunoelectron microscopic methods with monoclonal and polyclonal antibodies. The immunostaining revealed an intercellular plasma membrane and cytoplasmic labelling of the epidermal keratinocytes, but no labelling of Langerhans cells, melanocytes and Merkel cells. Large amounts of TNF alpha were regularly found in the sebaceous glands. These findings demonstrate that epidermal keratinocytes and especially sebocytes produce and release TNF alpha and that this keratinocyte-derived cytokine may be important for the …

AdultMalePathologymedicine.medical_specialtyImmunoelectron microscopymedicine.medical_treatmentDermatologyMicemedicineAnimalsHumansMicroscopy ImmunoelectronCellular localizationMice Inbred BALB Cintegumentary systemEpidermis (botany)biologyTumor Necrosis Factor-alphaGeneral MedicineMiddle AgedMolecular biologyImmunohistochemistryCytokinemedicine.anatomical_structurePolyclonal antibodiesbiology.proteinImmunohistochemistryFemaleEpidermisMerkel cellImmunostainingArchives of dermatological research
researchProduct

IgA anti-actin antibodies ELISA in coeliac disease: A multicentre study.

2007

Previous studies have demonstrated that serum anti-actin antibodies are a reliable marker of intestinal damage severity in coeliac disease.To validate in a multicentre study the clinical usefulness of serum IgA anti-actin antibody ELISA and its possible use in monitoring intestinal mucosa lesions during gluten-free diet.Four centres recruited 205 newly diagnosed coeliac disease patients with villous atrophy, 80 healthy controls and 81 "disease" controls. Twelve coeliac disease patients on gluten-free diet but with persistent symptoms underwent serum IgA anti-actin antibody assay and intestinal histology evaluation. IgA anti-actin antibody ELISA was performed with a commercial kit. All coeli…

AdultMalePathologymedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentEnzyme-Linked Immunosorbent AssaySerum igaDiseaseCommercial kitSensitivity and SpecificityCoeliac diseaseIgA anti-actin antibodies; coeliac disease; multicentre studyIntestinal mucosaHumansMedicineIntestinal MucosaVillous atrophyChildAgedAutoantibodiesHepatologybiologybusiness.industryGastroenterologyInfantnutritional and metabolic diseasesMiddle AgedIgA anti-actin antibodiemedicine.diseaseActinsmulticentre studyImmunoglobulin ACeliac DiseaseIntestinal histologyChild Preschoolbiology.proteinFemaleAntibodybusinessBiomarkerscoeliac disease
researchProduct